Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose.
OBJECTIVE
The goal in this study was to evaluate hearing preservation rates and to determine prognostic factors for this outcome following fractionated stereotactic radiotherapy (FSRT) of vestibular schwannoma.


METHODS
Thirty-four consecutive patients with serviceable hearing who received FSRT between May 1998 and December 2003 were identified. Clinical and audiometry data were collected prospectively. The prescription dose was 45 Gy in 25 fractions prescribed to the 90% isodose line. The median follow-up duration was 36.5 months (range 12-85 months). The actuarial 2- and 4-year local control rates were 100 and 95.7%, respectively. Permanent trigeminal and facial nerve complications were 0 and 6%, respectively. The actuarial 2- and 3-year serviceable hearing preservation rates were both 63%. The median loss in speech reception threshold was 15 dB (range--10 to 65 dB). The radiotherapy dose to the cochlea was the only significant prognostic factor for hearing deterioration. Radiotherapy dose to the cochlear nucleus, patient age, sex, pre-FSRT hearing grade, tumor volume, and intracanalicular tumor volume failed to show any significance as prognostic factors.


RESULTS
Five cases were replanned with four different radiotherapy techniques (namely arcs, dynamic arcs, static conformal fields, and intensity-modulated radiotherapy), with the cochlea defined as an organ at risk. In all cases, replanning resulted in statistically significant reduction in radiation to the cochlea (p = 0.001); however, no single replanning technique was found to be superior.


CONCLUSIONS
The radiation dose to the cochlea is strongly predictive for subsequent hearing deterioration. It is essential for the cochlea to be outlined as an organ at risk, and for radiation techniques to be optimized, to improve long-term hearing preservation.
Thomas
Carys
C
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Di Maio
Salvatore
S
Ma
Roy
R
Vollans
Emily
E
Chu
Christina
C
Clark
Brenda
B
Lee
Richard
R
McKenzie
Michael
M
Martin
Montgomery
M
Toyota
Brian
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D003051:Cochlea / Q000528:radiation effects*; D005154:Facial Nerve / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006309:Hearing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009464:Neuroma, Acoustic / Q000532:radiotherapy*; D011379:Prognosis; D011446:Prospective Studies; D011829:Radiation Dosage; D016634:Radiosurgery; D014276:Trigeminal Nerve / Q000502:physiology